BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 14726584)

  • 21. Fragile sites are preferential targets for integrations of MLV vectors in gene therapy.
    Bester AC; Schwartz M; Schmidt M; Garrigue A; Hacein-Bey-Abina S; Cavazzana-Calvo M; Ben-Porat N; Von Kalle C; Fischer A; Kerem B
    Gene Ther; 2006 Jul; 13(13):1057-9. PubMed ID: 16511518
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Gene therapy. RAC hears a plea for resuming trials, despite cancer risk.
    Kaiser J
    Science; 2003 Feb; 299(5609):991. PubMed ID: 12586909
    [No Abstract]   [Full Text] [Related]  

  • 23. Success for gene therapy: render unto Caesar that which is Caesar's.
    Qiao J; Diaz RM; Vile RG
    Genome Biol; 2004; 5(8):237. PubMed ID: 15287968
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Methodology of gene therapy: adverse events and further technological developments].
    Hamada H
    Nihon Rinsho; 2010 Aug; 68 Suppl 8():601-6. PubMed ID: 20979308
    [No Abstract]   [Full Text] [Related]  

  • 25. Harmful potential of viral vectors fuels doubts over gene therapy.
    Check E
    Nature; 2003 Jun; 423(6940):573-4. PubMed ID: 12789298
    [No Abstract]   [Full Text] [Related]  

  • 26. A tragic setback.
    Check E
    Nature; 2002 Nov; 420(6912):116-8. PubMed ID: 12432357
    [No Abstract]   [Full Text] [Related]  

  • 27. Ectopic retroviral expression of LMO2, but not IL2Rgamma, blocks human T-cell development from CD34+ cells: implications for leukemogenesis in gene therapy.
    Pike-Overzet K; de Ridder D; Weerkamp F; Baert MR; Verstegen MM; Brugman MH; Howe SJ; Reinders MJ; Thrasher AJ; Wagemaker G; van Dongen JJ; Staal FJ
    Leukemia; 2007 Apr; 21(4):754-63. PubMed ID: 17268520
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Gene therapy for primary immunodeficiency diseases].
    Ariga T
    Nihon Rinsho; 2005 Dec; 63 Suppl 12():641-5. PubMed ID: 16416867
    [No Abstract]   [Full Text] [Related]  

  • 29. Gene therapists hopeful as trials resume with childhood disease.
    Check E
    Nature; 2004 Jun; 429(6992):587. PubMed ID: 15190314
    [No Abstract]   [Full Text] [Related]  

  • 30. [Hematopoietic malignancies and gene therapy].
    Ozawa K
    Gan To Kagaku Ryoho; 2003 Apr; 30(4):478-82. PubMed ID: 12722677
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Success and setback: another adverse event.
    Verma IM
    Mol Ther; 2002 Nov; 6(5):565-6. PubMed ID: 12409253
    [No Abstract]   [Full Text] [Related]  

  • 32. Gene therapy: is IL2RG oncogenic in T-cell development?
    Pike-Overzet K; de Ridder D; Weerkamp F; Baert MR; Verstegen MM; Brugman MH; Howe SJ; Reinders MJ; Thrasher AJ; Wagemaker G; van Dongen JJ; Staal FJ
    Nature; 2006 Sep; 443(7109):E5; discussion E6-7. PubMed ID: 16988660
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Gene therapy: X-SCID transgene leukaemogenicity.
    Thrasher AJ; Gaspar HB; Baum C; Modlich U; Schambach A; Candotti F; Otsu M; Sorrentino B; Scobie L; Cameron E; Blyth K; Neil J; Abina SH; Cavazzana-Calvo M; Fischer A
    Nature; 2006 Sep; 443(7109):E5-6; discussion E6-7. PubMed ID: 16988659
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Gene therapy. Second child in French trial is found to have leukemia.
    Marshall E
    Science; 2003 Jan; 299(5605):320. PubMed ID: 12531981
    [No Abstract]   [Full Text] [Related]  

  • 35. The leukemogenic risk of integrating retroviral vectors in hematopoietic stem cell gene therapy applications.
    Kang EM; Tisdale JF
    Curr Hematol Rep; 2004 Jul; 3(4):274-81. PubMed ID: 15217557
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Is retroviral gene marking too dangerous to use?
    Brenner MK; Heslop HE
    Cytotherapy; 2003; 5(3):190-3. PubMed ID: 12850996
    [No Abstract]   [Full Text] [Related]  

  • 37. Retroviral vectors: new applications for an old tool.
    Barquinero J; Eixarch H; PĂ©rez-Melgosa M
    Gene Ther; 2004 Oct; 11 Suppl 1():S3-9. PubMed ID: 15454951
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Gene therapy: therapeutic gene causing lymphoma.
    Woods NB; Bottero V; Schmidt M; von Kalle C; Verma IM
    Nature; 2006 Apr; 440(7088):1123. PubMed ID: 16641981
    [TBL] [Abstract][Full Text] [Related]  

  • 39. SCID trials to remain on the 'bubble'.
    Mandavilli A
    Nat Med; 2003 Mar; 9(3):251. PubMed ID: 12612562
    [No Abstract]   [Full Text] [Related]  

  • 40. US panel advises resumption of gene trials.
    Fox JL
    Nat Biotechnol; 2002 Nov; 20(11):1068-9. PubMed ID: 12410240
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.